Although we demonstrate a correlation between BRAF mutation and upregulation of specific carbohydrate ligands for the C-type lectin MGL, there is an apparent discrepancy between the high amount of 76% of patients that carry MGL-binding glycans (Figures 1 and 2) and the estimated incidence of BRAF mutations in approximately 10% of CRC patients. This evidence concerns the gene CLEC10A and colorectal carcinoma.